ANI Pharmaceuticals (ANIP)  said it completed its planned acquisition of Alimera Sciences (NASDAQ:ALIM). Under the terms of ...

Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a ...

The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with ...

PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ANIP) (“ANI” or the “Company”) announced today that the Company ...

ANI Pharmaceuticals (ANIP) said it completed its planned acquisition of Alimera Sciences (NASDAQ:ALIM). Under the terms of the merger agreement, ANI acquired all of the outstanding shares of ...

Oren Livnat has given his Buy rating due to a combination of factors including the recent acquisition of Alimera Sciences by ANI Pharmaceuticals, which is expected to be immediately accretive to the ...

Alpharetta-based Alimera (NASDAQ:ALIM) Sciences Inc. (NASDAQ:ALIM) has finalized its merger with ANI Pharmaceuticals (NASDAQ:ANIP), Inc., as announced in a recent SEC filing. The pharmaceutical ...

16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced the completion of its previously announced acquisition of Alimera Sciences ...

Alpharetta-based Alimera (NASDAQ:ALIM) Sciences Inc. (NASDAQ:ALIM) has finalized its merger with ANI Pharmaceuticals (NASDAQ:ANIP), Inc., as announced in a recent SEC filing. The pharmaceutical ...

PRINCETON - ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), a diversified biopharmaceutical company, announced today the finalization of its acquisition process for Alimera (NASDAQ:ALIM) Sciences, Inc.